0	12	Requirements	requirement	NNS
13	16	for	for	IN
17	26	induction	induction	NN
27	29	of	of	IN
30	37	vitamin	vitamin	NN
38	48	D-mediated	d-mediated	JJ
49	53	gene	gene	NN
54	64	regulation	regulation	NN
65	67	in	in	IN
68	74	normal	normal	JJ
75	80	human	human	JJ
81	82	B	b	NN
83	94	lymphocytes	lymphocyte	NNS
94	95	.	.	.

97	103	Mature	mature	JJ
104	109	human	human	JJ
110	121	lymphocytes	lymphocyte	NNS
122	125	are	be	VBP
126	132	unique	unique	JJ
133	140	targets	target	NNS
141	143	of	of	IN
144	145	1	1	CD
146	171	alpha,25-dihydroxyvitamin	alpha,25-dihydroxyvitamin	NN
172	174	D3	d3	NN
175	176	(	(	(
176	177	1	1	CD
178	194	alpha,25(OH)2D3)	alpha,25(oh)2d3)	NN
195	197	in	in	IN
198	202	that	that	DT
203	210	vitamin	vitamin	NN
211	212	D	D	NNP
213	222	receptors	receptor	NNS
223	224	(	(	(
224	227	VDR	VDR	NNP
227	228	)	)	)
229	232	are	be	VBP
233	236	not	not	RB
237	251	constitutively	constitutively	RB
252	261	expressed	express	VBN
261	262	,	,	,
263	266	and	and	CC
267	275	specific	specific	JJ
276	284	cellular	cellular	JJ
285	295	activation	activation	NN
296	303	signals	signal	NNS
304	307	are	be	VBP
308	316	required	require	VBN
317	320	for	for	IN
321	325	both	both	CC
326	329	the	the	DT
330	343	up-regulation	up-regulation	NN
344	346	of	of	IN
347	350	VDR	VDR	NNP
351	354	and	and	CC
355	368	establishment	establishment	NN
369	371	of	of	IN
372	382	reactivity	reactivity	NN
383	385	to	to	TO
386	389	the	the	DT
390	400	lipophilic	lipophilic	JJ
401	407	ligand	ligand	NN
407	408	.	.	.

409	418	Treatment	Treatment	NNP
419	421	of	of	IN
422	423	B	B	NNP
424	435	lymphocytes	lymphocyte	NNS
436	440	with	with	IN
441	444	the	the	DT
445	453	cytokine	cytokine	NN
454	458	IL-4	il-4	NN
459	460	(	(	(
460	464	IL-4	il-4	NN
464	465	)	)	)
465	466	,	,	,
467	469	in	in	IN
470	473	the	the	DT
474	481	absence	absence	NN
482	484	of	of	IN
485	490	prior	prior	JJ
491	501	activation	activation	NN
501	502	,	,	,
503	510	induces	induce	VBZ
511	512	a	a	DT
513	517	weak	weak	JJ
518	531	up-regulation	up-regulation	NN
532	534	of	of	IN
535	538	VDR	VDR	NNP
539	549	expression	expression	NN
550	553	but	but	CC
554	559	fails	fail	VBZ
560	562	to	to	TO
563	571	generate	generate	VB
572	579	vitamin	vitamin	NN
580	592	D-responsive	d-responsive	JJ
593	600	element	element	NN
601	602	(	(	(
602	616	VDRE)-reactive	vdre)-reactive	JJ
617	624	nuclear	nuclear	JJ
625	632	protein	protein	NN
633	642	complexes	complex	NNS
643	645	or	or	CC
646	648	to	to	TO
649	657	initiate	initiate	VB
658	661	the	the	DT
662	669	genomic	genomic	JJ
670	683	transcription	transcription	NN
684	686	of	of	IN
687	704	25-hydroxyvitamin	25-hydroxyvitamin	NN
705	707	D3	d3	NN
708	722	24-hydroxylase	24-hydroxylase	NN
722	723	.	.	.

724	735	Stimulation	stimulation	NN
736	738	of	of	IN
739	740	B	B	NNP
741	752	lymphocytes	lymphocyte	NNS
753	755	by	by	IN
756	762	either	either	CC
763	771	ligation	ligation	NN
772	774	of	of	IN
775	779	CD40	CD40	NNP
780	782	Ag	Ag	NNP
783	785	or	or	CC
786	799	cross-linking	cross-linke	VBG
800	803	the	the	DT
804	806	Ig	Ig	NNP
807	815	receptor	receptor	NN
816	818	is	be	VBZ
819	823	also	also	RB
824	836	insufficient	insufficient	JJ
837	839	to	to	TO
840	846	render	render	VB
847	848	B	B	NNP
849	860	lymphocytes	lymphocyte	NNS
861	871	responsive	responsive	JJ
872	874	to	to	TO
875	876	1	1	CD
877	892	alpha,25(OH)2D3	alpha,25(oh)2d3	NN
892	893	.	.	.

894	901	However	however	RB
901	902	,	,	,
903	907	this	this	DT
908	916	apparent	apparent	JJ
917	921	lack	lack	NN
922	924	of	of	IN
925	933	response	response	NN
934	936	to	to	TO
937	940	the	the	DT
941	951	secosterol	secosterol	NN
952	955	can	can	MD
956	958	be	be	VB
959	967	overcome	overcome	VBN
968	970	by	by	IN
971	982	stimulation	stimulation	NN
983	985	of	of	IN
986	987	B	B	NNP
988	999	lymphocytes	lymphocyte	NNS
1000	1004	with	with	IN
1005	1006	a	a	DT
1007	1018	combination	combination	NN
1019	1021	of	of	IN
1022	1027	these	these	DT
1028	1036	cellular	cellular	JJ
1037	1047	activation	activation	NN
1048	1055	signals	signal	NNS
1055	1056	,	,	,
1057	1062	which	which	WDT
1063	1066	are	be	VBP
1067	1077	sufficient	sufficient	JJ
1078	1080	to	to	TO
1081	1085	lead	lead	VB
1086	1088	to	to	TO
1089	1091	G1	g1	NN
1092	1096	cell	cell	NN
1097	1102	cycle	cycle	NN
1103	1114	progression	progression	NN
1114	1115	.	.	.

1116	1118	In	in	IN
1119	1122	the	the	DT
1123	1131	presence	presence	NN
1132	1134	of	of	IN
1135	1136	1	1	CD
1137	1152	alpha,25(OH)2D3	alpha,25(oh)2d3	NN
1152	1153	,	,	,
1154	1162	cellular	cellular	JJ
1163	1173	activation	activation	NN
1174	1184	associated	associate	VBN
1185	1189	with	with	IN
1190	1201	stimulation	stimulation	NN
1202	1204	of	of	IN
1205	1209	such	such	JJ
1210	1211	a	a	DT
1212	1223	progression	progression	NN
1224	1231	appears	appear	VBZ
1232	1234	to	to	TO
1235	1237	be	be	VB
1238	1248	sufficient	sufficient	JJ
1249	1252	for	for	IN
1253	1256	the	the	DT
1257	1270	up-regulation	up-regulation	NN
1271	1273	of	of	IN
1274	1277	VDR	VDR	NNP
1278	1285	message	message	NN
1286	1289	and	and	CC
1290	1297	protein	protein	NN
1298	1301	and	and	CC
1302	1311	necessary	necessary	JJ
1312	1315	for	for	IN
1316	1319	the	the	DT
1320	1333	establishment	establishment	NN
1334	1336	of	of	IN
1337	1341	VDRE	VDRE	NNP
1342	1349	binding	binding	NN
1350	1359	complexes	complex	NNS
1360	1363	and	and	CC
1364	1367	the	the	DT
1368	1377	induction	induction	NN
1378	1380	of	of	IN
1381	1395	24-hydroxylase	24-hydroxylase	NN
1396	1403	message	message	NN
1403	1404	.	.	.

1405	1416	Furthermore	furthermore	RB
1416	1417	,	,	,
1418	1426	biologic	biologic	JJ
1427	1436	functions	function	NNS
1437	1440	are	be	VBP
1441	1450	modulated	modulate	VBN
1450	1451	,	,	,
1452	1454	in	in	IN
1455	1459	that	that	IN
1460	1463	the	the	DT
1464	1471	hormone	hormone	NN
1472	1480	inhibits	inhibit	VBZ
1481	1494	proliferation	proliferation	NN
1495	1497	in	in	IN
1498	1499	a	a	DT
1500	1506	subset	subset	NN
1507	1509	of	of	IN
1510	1513	the	the	DT
1514	1523	activated	activate	VBN
1524	1525	B	b	NN
1526	1531	cells	cell	NNS
1531	1532	.	.	.

1533	1538	These	these	DT
1539	1551	observations	observation	NNS
1552	1559	suggest	suggest	VBP
1560	1564	that	that	IN
1565	1575	reactivity	reactivity	NN
1576	1578	to	to	TO
1579	1580	1	1	CD
1581	1596	alpha,25(OH)2D3	alpha,25(oh)2d3	NN
1597	1599	is	be	VBZ
1600	1607	tightly	tightly	RB
1608	1617	regulated	regulate	VBN
1618	1620	in	in	IN
1621	1622	B	B	NNP
1623	1634	lymphocytes	lymphocyte	NNS
1634	1635	,	,	,
1636	1645	requiring	require	VBG
1646	1654	specific	specific	JJ
1655	1662	signals	signal	NNS
1663	1666	for	for	IN
1667	1670	its	its	PRP$
1671	1681	initiation	initiation	NN
1681	1682	.	.	.